Ursprung des Netzwerks ersten Grades von Martin Johnson
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Quanta Dialysis Technologies Ltd.
 Quanta Dialysis Technologies Ltd. Medical SpecialtiesHealth Technology Quanta Dialysis Technologies Ltd. develops haemodialysis systems. The firm's SC+ is a performance, portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines. It offers SelfCare+, a haemodialysis machine for dialysis patients to control their disease and determine the treatment regime and care. The company was founded by Clive Henrey Buckberry, John Eric Milad and Martin Johnson in 2008 and is headquartered in Alcester, the United Kingdom.
3
| Holding Company | Medical Specialties | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Martin Johnson
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Pharmaceuticals: Major | Director of Finance/CFO | |
| The University of Chicago | College/University | Undergraduate Degree | |
Stage Capital Ventures
 Stage Capital Ventures Investment ManagersFinance Stage Capital Ventures is a Venture Capital firm, a subsidiary of NBGI Private Equity Ltd. founded in 2000 by Aris Constantinides. Stage Capital Ventures is headquartered in Boca Raton. | Investment Managers | Private Equity Investor | |
| BONESUPPORT HOLDING AB | Medical Specialties | Director/Board Member | |
| SYMETIS SA | Biotechnology | Director/Board Member | |
| CELLNOVO | Medical Specialties | Director/Board Member | |
ERS Genomics Ltd.
 ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Biotechnology | Chief Executive Officer | |
| University of Warwick | College/University | Graduate Degree |
Statistik
International
| Schweiz | 3 |
| Vereinigtes Königreich | 3 |
| Vereinigte Staaten | 2 |
| Griechenland | 2 |
| Schweden | 2 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 3 |
| Finance | 3 |
Operativ
| Director/Board Member | 4 |
| Undergraduate Degree | 2 |
| Chief Executive Officer | 2 |
| Founder | 2 |
| Director of Finance/CFO | 1 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Martin Johnson
- Unternehmensverbindungen
